Search PubMed⌕ Search

Biomedical subjects

M Kumar

Publications and source records attributed to M Kumar.

At least 271 records · Page 15Linked to original sources
PubMed1988

Synthesis, characterization, and antitumor activity of iron(II) and iron(III) complexes of alpha-N-heterocyclic carboxaldehyde thiosemicarbazones.

Complexes of iron(II) and iron(III) with 1-formylisoquinoline thiosemicarbazone (1-iqtsc-H), 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (4-Me-5-NH2-1-iqtsc-H) and 4-(m-aminophenyl)-2-formylpyridine thiosemicarbazone (4-m-NH2ph-2-pytsc-H) were synthesized and characterized by elemental analysis, conductance measurements, magnetic susceptibilities (from room temperature down to liquid N2 temperature), and Mössbauer, electronic, and infrared spectral studies. On the basis of these studies, a highly distorted, high-spin, five-coordinate structure for Fe(HL)SO4 (HL = 1-iqtsc-H, 4-Me-5-NH2-1-iqtsc-H or 4-m-NH2ph-2-pytsc-H) and a distorted, low-spin, octahedral structure for Fe(HL)Cl2 are suggested. The EPR spectra of iron(III) complexes show that all have dxy low-spin ground state. All these complexes have been screened for their antitumor activity against the P 388 lymphocytic leukemia test system in mice and have been found to possess significant activity at the dosages employed.

Animals↗
PubMed1988

Serum IgG brain reactive antibodies in Alzheimer disease and Down syndrome.

The cause(s) of Alzheimer disease (AD) remain unknown. Since neurofibrillary tangles and neuritic plaques, a hallmark of AD, are also present in older patients with Down syndrome (DS), a close relationship between the two diseases has been suggested. IgG type of brain reactive antibodies (BRAs) are present in a majority of patients with AD but such studies have not been carried out in adult patients with DS. The present study was carried out to test the hypothesis that if the brain changes in older patients with DS and patients with AD are identical, the occurrence and specificity of BRAs should be similar in both diseases. The frequency of BRAs was studied in sera obtained from 21 patients with AD, 26 older patients with DS, and 20 normal control subjects using electroblots prepared from rat spinal cord proteins. Circulating BRAs were found in 57% of patients with AD, 81% of patients with DS, and 30% of normal controls. However, the pattern of BRA reactivity was different in AD and DS. In AD, antibodies reacted with the 200-kDa subunit of neurofilament triplet singly or in combination with the 150-kDa, 70-kDa or with the associated 62-kDa protein. In DS, BRAs always reacted with the 70-kDa protein, usually in combination with the 200-kDa subunit and, less frequently, in association with the other subunits. No specific pattern of antibody activity was evident in the control group.

Adult↗
PubMed1988

Drusen and drusenoid macular lesions.

Yellow-colored lesions with a similar appearance at the level of the retinal pigment epithelium are frequently called drusen. Direct and indirect ophthalmoscopy, slit-lamp and contact lens examination, and fluorescein angiography allow differentiation among true drusen, retinal-pigment-epithelial detachments, and deposits secondary to retinal-pigment-epithelial degeneration. A combination of these lesions may be present in a single eye especially in patients with age-related macular degeneration. It is important to distinguish among these lesions because prognosis and treatment potential vary.

Adult↗
PubMed1988

Rifampicin induced uterine bleeding.

A case of uterine bleeding after intake of rifampicin is reported in a 35-year-old female. Provocation test was also positive. The underlying mechanism whether it was a hypersensitivity phenomenon like fixed drug eruption or due to induction of uterine acyl-hydrolase enzyme, is not clear. Uterine bleeding has not been observed as a side-effect of rifampicin in the past.

Adult↗
PubMed1987

Long-term survival in patients with Ewing's sarcoma relapsing after completing therapy.

While the proportion of patients with Ewing's sarcoma attaining and maintaining long-term remission has markedly improved, a proportion of patients suffer relapse of the tumor. In our experience relapses may occur late in the course of the disease, approximately 20% of those at risk beyond 5 years having recurrence of tumor. Review of our data indicates that for patients relapsing after therapy has been discontinued, the probability of attaining second remission is high (0.84) and that a significant proportion of these patients attaining second complete remission will survive their disease (0.60).

Child↗
PubMed1987

Sequential radiation changes in cytology of vaginal smears in carcinoma of cervix uteri during radiotherapy.

The study deals with acute/immediate radiation changes in 2020 sequential vaginal smears in 101 patients of carcinoma of the cervix uteri, 97 were of squamous cell carcinoma and 4 of adenocarcinoma. The smears were collected after 12-14 days, 15-24 days and 25 days to 6 weeks following radiotherapy. The pretreatment vaginal smears were collected and examined for percentage of cancer cells. Subsequent smears were studied for radiation changes in benign and malignant cells, such as cell size, vacuolation of cytoplasm, multinucleation and nuclear changes, etc. A gradual and linear decline in cancer cells was observed until the end of therapy; 41.6% of patients had less than 10% cancer cells within 12-14 days of therapy, 63.4% of patients between 15 and 24 days and 74.6% after 25 days to 6 weeks following radiation. Eighty three percent of the patients attained zero level at the end of therapy.

Adenocarcinoma↗